These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7973210)

  • 21. Triangular test and randomized trials: practical problems in a small cell lung cancer trial.
    Pignon JP; Tarayre M; Auquier A; Arriagada R; Le Chevalier T; Ruffié P; Rivière A; Monnet I; Chomy P; Tuchais C
    Stat Med; 1994 Jul 15-30; 13(13-14):1415-21. PubMed ID: 7973221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stopping trials for efficacy: an almost unbiased view.
    Goodman SN
    Clin Trials; 2009 Apr; 6(2):133-5. PubMed ID: 19342465
    [No Abstract]   [Full Text] [Related]  

  • 23. [San Antonio Breast Cancer Symposium 2003. New therapeutic prospects in the treatment of early-stage breast cancer].
    Montemurro F
    Tumori; 2004; 90(1):suppl 1-16. PubMed ID: 15143995
    [No Abstract]   [Full Text] [Related]  

  • 24. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 25. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 26. Strength of accumulating evidence and data monitoring committee decision making.
    George SL; Freidlin B; Korn EL
    Stat Med; 2004 Sep; 23(17):2659-72. PubMed ID: 15316949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Select-drop designs in clinical trials.
    Ellenberg SS
    Am Heart J; 2000 Apr; 139(4):S158-60. PubMed ID: 10740123
    [No Abstract]   [Full Text] [Related]  

  • 28. [ASCO 2006 Gastrointestinal Cancers Symposium, San Francisco, 26-28 January 2006].
    Tumori; 2006; 92(2):1-20. PubMed ID: 16724704
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: All-cause mortality in randomized trials of cancer screening.
    Parker C; Dearnaley D
    J Natl Cancer Inst; 2002 Jun; 94(11):861-2; author reply 865-6. PubMed ID: 12048276
    [No Abstract]   [Full Text] [Related]  

  • 30. [Chemotherapy in patients with colorectal carcinoma: applicability of data from clinical trials for the individual patient].
    Thürmann PA
    Zentralbl Chir; 2008 Feb; 133(1):25-30. PubMed ID: 18278698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Celebrate or calibrate? We say calibrate.
    Ajani JA; Blum MA; Welsh J; Hofstetter WL; Swisher SG
    J Clin Oncol; 2011 Jul; 29(19):2732; author reply 2732-3. PubMed ID: 21606421
    [No Abstract]   [Full Text] [Related]  

  • 32. [On ''Multimodal treatment of clinical non-small cell N2 bronchogenic carcinoma: what is the answer?''].
    González Aragoneses F
    Arch Bronconeumol; 2007 Mar; 43(3):183-4; author reply 184. PubMed ID: 17386198
    [No Abstract]   [Full Text] [Related]  

  • 33. Bias and trials stopped early for benefit.
    Goodman S; Berry D; Wittes J
    JAMA; 2010 Jul; 304(2):157; author reply 158-9. PubMed ID: 20628126
    [No Abstract]   [Full Text] [Related]  

  • 34. Early viewing of noninferiority trials in progress.
    Dignam JJ
    J Clin Oncol; 2005 Aug; 23(24):5461-3. PubMed ID: 16027438
    [No Abstract]   [Full Text] [Related]  

  • 35. When an interim analysis of randomized trial changes the practice in oncology: The lesson of adjuvant trastuzumab and the HERA trial.
    De Rossi C; Brunello A; Jirillo G; Jirillo A
    Immunopharmacol Immunotoxicol; 2009; 31(1):1-4. PubMed ID: 19238693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of docetaxel in the adjuvant chemotherapy of breast cancer].
    Fattoruso SI; Rossi S; Di Lauro L; Botti C; Vici P; Lopez M
    Clin Ter; 2008; 159(5):369-76. PubMed ID: 18998039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial.
    Tremont-Lukats IW; Teixeira GM
    Cancer; 1996 Dec; 78(11):2450-3. PubMed ID: 8941020
    [No Abstract]   [Full Text] [Related]  

  • 38. [ASCO 2006 Annual Meeting, Atlanta, June 2-6, 2006. Focus on gastrointestinal tumors].
    Bonetti A; Cascinu S; Falcone A; Zaniboni A
    Tumori; 2006; 92(4):suppl 10-43. PubMed ID: 17036537
    [No Abstract]   [Full Text] [Related]  

  • 39. Choice of control group in randomised trials of cancer medicine: are we testing trivialities?
    Tao D; Prasad V
    Lancet Oncol; 2018 Sep; 19(9):1150-1152. PubMed ID: 30191836
    [No Abstract]   [Full Text] [Related]  

  • 40. [Medical treatment of primary breast cancer: new targeted biological treatments].
    Andersson M; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3082-4. PubMed ID: 17877953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.